Yen-Shen Lu

ScholarGPS® ID: 61894731554202

Affiliation

National Taiwan University, Taipei City, Taiwan

Affiliation History

Field

Medicine

Discipline

Oncology

Top Specialties

Metrics Summary

Publication Count

174

Predicted Citations

8,550

Predicted h-index

Ranking

Publications and Citation History

Publications based on Top Specialties

Types of Publication

Publications
Books
Patents
NIH/NSF

Add Delete
Trastuzumab deruxtecan versus treatment of physician’s choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study (journal article) Yamashita, Toshinari \| Sohn, Joo Hyuk \| Tokunaga, Eriko \| Niikura, Naoki \| Park, Yeon Hee \| Lee, Keun Seok \| Chae, Yee Soo \| Xu, Binghe \| Wang, Xiaojia \| Im, Seock-Ah \| ... \| Tsurutani, Junji Breast Cancer (2024). 10.1007/s12282-024-01600-7 Cite \| Source
Valid Analysis of Brain-Specific Progression-Free Survival—Reply (journal article) Chen, Tom Wei-Wu \| Dai, Ming-Shen \| Lu, Yen-Shen JAMA Oncology (2024). 10.1001/jamaoncol.2024.1699 Cite \| Source
In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment (journal article) Lien, Huang-Chun \| Lo, Chiao \| Lee, Yi-Hsuang \| Lin, Po-Hang \| Wang, Ming-Yang \| Kuo, Wen-Hung \| Tsai, Li-Wei \| Lu, Yen-Shen \| Hu, Hsiang-Wei \| Li, Yu-Chia \| Huang, Chiun-Sheng Breast Cancer Research, volume 26, issue 1 (2024). 10.1186/s13058-024-01852-3 Cite \| Source
pionERA Breast Cancer (BC): Phase III study of first-line (1L) giredestrant vs. fulvestrant, both combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), in patients (pts) with estrogen receptor-positive (ER+), HER2– locally advanced/metastatic B (journal article) Kalinsky, Kevin \| Jeselsohn, Rinath \| Bellet, Meritxell \| Fasching, Peter A. \| Gomez-Abuin, Gonzalo \| Jung, Kyung Hae \| Lavallé, Sandrine \| López-Valverde, Vanesa \| Lu, Yen-Shen \| Schwab, Richard B. \| ... \| Andre, Fabrice Journal of Clinical Oncology, volume 42, issue 16_suppl, pages TPS1130-TPS1130 (2024). 10.1200/JCO.2024.42.16_suppl.TPS1130 Cite \| Source
Quantifying payloads of antibody‒drug conjugates using a postcolumn infused-internal standard strategy with LC‒MS (journal article) Cheng, Chih-Ning \| Liao, Hsiao-Wei \| Lin, Ching-Hung \| Chang, Wen-Chi \| Chen, I-Chun \| Lu, Yen-Shen \| Kuo, Ching-Hua Analytica Chimica Acta, volume 1303 (2024). 10.1016/j.aca.2024.342537 Cite \| Source
miR-622 Increases miR-30a Expression through Inhibition of Hypoxia-Inducible Factor 1α to Improve Metastasis and Chemoresistance in Human Invasive Breast Cancer Cells (journal article) Cheng, Chun-Wen \| Liu, Yu-Fan \| Liao, Wen-Ling \| Chen, Po-Ming \| Hung, Yueh-Tzu \| Lee, Huei-Jane \| Cheng, Yu-Chun \| Wu, Pei-Ei \| Lu, Yen-Shen \| Shen, Chen-Yang Cancers, volume 16, issue 3, pages 657- (2024). 10.3390/cancers16030657 Cite \| Source
A novel computer-assisted tool for 3D imaging of programmed death-ligand 1 expression in immunofluorescence-stained and optically cleared breast cancer specimens (journal article) Lee, Yi-Hsuan \| Huang, Chung-Yen \| Hsieh, Yu-Han \| Yang, Chia-Hung \| Hung, Yu-Ling \| Chen, Yung-An \| Lin, Yu-Chieh \| Lin, Ching-Hung \| Lee, Jih-Hsiang \| Wang, Ming-Yang \| ... \| Lu, Yen-Shen BMC Cancer, volume 24, issue 1 (2024). 10.1186/s12885-023-11748-8 Cite \| Source
57MO First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in HR+/HER2− advanced breast cancer (ABC): A post hoc analysis of Asian and non-Asian patients (pts) from the phase II RIGHT choice trial (journal article) Yap, Y-S. \| Im, S-A. \| Lu, Y-S. \| Azim, H.A. \| Eralp, Y. \| Kanakasetty, G.B. \| Abdel-Razeq, H. \| Zhukova, L. \| Thuerigen, A. \| Delgar Alfaro, T. \| ... \| El Saghir, N.S. Annals of Oncology, volume 34 (2023). 10.1016/j.annonc.2023.10.192 Cited by (1) \| Cite \| Source
23P Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP) (journal article) Lee, S.C. \| Park, Y.H. \| Singer, C. \| Balmaña, J. \| Dent, R.A. \| Tan, V.K. \| Sari, N.A.M. \| Md Yusof, M. \| Que, F.V.F. \| Lu, Y-S. \| ... \| Kim, H.J. Annals of Oncology, volume 34 (2023). 10.1016/j.annonc.2023.10.155 Cite \| Source
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials (journal article) André, F. \| Su, F. \| Solovieff, N. \| Hortobagyi, G. \| Chia, S. \| Neven, P. \| Bardia, A. \| Tripathy, D. \| Lu, Y.-S. \| Lteif, A. \| ... \| Arteaga, C.L. Annals of Oncology, volume 34, issue 11, pages 1003-1014 (2023). 10.1016/j.annonc.2023.08.011 Cited by (5) \| Cite \| Source
Disparity in survival benefits of pembrolizumab between Asian and non‐Asian patients with advanced cancers: A systematic review and meta‐regression analysis (journal article) Peng, Shang‐Hsuan \| Lin, Ching‐Hung \| Chen, I‐Chun \| Shen, Ying‐Chun \| Chang, Dwan‐Ying \| Chen, Tom Wei‐Wu \| Huang, Shu‐Min \| Hu, Fu‐Chang \| Lu, Yen‐Shen Cancer Medicine, volume 12, issue 19, pages 20035-20051 (2023). 10.1002/cam4.6563 Cite \| Source
456P Quality of life (QOL) analysis from the phase II RIGHT choice study of first-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC) (journal article) Eralp, Y. \| Abdel-Razeq, H. \| Im, S-A. \| Rihani, J. \| Lu, Y-S. \| Yap, Y.S. \| Azim, H.A. \| Prasongsook, N. \| Zhukova, L. \| Hu, H. \| ... \| El Saghir, N.S. Annals of Oncology, volume 34 (2023). 10.1016/j.annonc.2023.09.632 Cite \| Source
402P First-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice stu (journal article) Azim, H.A. \| El Saghir, N.S. \| Yap, Y.S. \| Eralp, Y. \| Im, S-A. \| Sandhu, M.S. \| Abdel-Razeq, H. \| Gupta, S. \| Artamonova, E. \| Rihani, J. \| ... \| Lu, Y-S. Annals of Oncology, volume 34 (2023). 10.1016/j.annonc.2023.09.579 Cited by (2) \| Cite \| Source
Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer (journal article) Chen, Tom Wei-Wu \| Hsiao, Wen \| Dai, Ming-Shen \| Lin, Ching-Hung \| Chang, Dwan-Ying \| Chen, I-Chun \| Wang, Ming-Yang \| Chang, Shu-Han \| Huang, Shu-Min \| Cheng, Ann-Lii \| ... \| Lu, Yen-Shen Breast Cancer Research and Treatment, volume 201, issue 3, pages 377-385 (2023). 10.1007/s10549-023-06967-3 Cite \| Source
Assessing the Relationship Between Persistent Organic Pollutants in Adipose Tissue and Female Breast Cancer Risk in Taiwan: A Prioritization Study (journal article) Tsai, Meng Shan \| Kuo, Wen Hung \| Chen, Chi Jen \| Li, Szu Yi \| Chang, Yung Chun \| Wang, Ming Yang \| Lu, Yen Shen \| Wang, Shu Li \| Lin, Ching Hung \| Chen, Pau Chung ISEE Conference Abstracts, volume 2023, issue 1 (2023). 10.1289/isee.2023.FP-084 Cite \| Source
The relation between air pollution exposure and breast cancer risk: a case-control study in Taiwan (journal article) Lee, Chen \| Kuo, Wen Hung \| Ho, Chi Chang \| Li, Szu Yi \| Wang, Ming Yang \| Wang, Ming Yang \| Lu, Yen Shen \| Lu, Yen Shen \| Lin, Ching Hung \| Lin, Ching Hung \| ... \| Chen, Pau Chung ISEE Conference Abstracts, volume 2023, issue 1 (2023). 10.1289/isee.2023.FP-083 Cite \| Source
Lifestyle Factors and Energy Intakes with Risks of Breast Cancer among Pre- and Post- Menopausal Women in Taiwan (journal article) Huang, Meng-Chuan \| Huang, Tz-Ting \| Feng, Hsin-Chun \| Chen, I-Chun \| Chang, Chiao-I \| Wang, Tsu-Nai \| Kuo, Wen-Hung \| Wang, Ming-Yang \| Tsai, Li-Wei \| Li, Szu-Yi \| ... \| Lin, Ching-Hung Nutrients, volume 15, issue 18, pages 3900- (2023). 10.3390/nu15183900 Cited by (2) \| Cite \| Source
ORACLE-RIPA study: A phase II, randomized, open-label, parallel-group study comparing the immune modulation effect of neoadjuvant ribociclib, palbociclib, and abemaciclib in early ER+/HER2- breast cancer. (journal article) Chen, I-Chun \| Lin, Ching-Hung \| Chang, Dwan-Ying \| Chen, Tom Wei-Wu \| Ma, Wei-li \| Wang, Ming-Yang \| Lu, Yen-Shen Journal of Clinical Oncology, volume 41, issue 16_suppl, pages TPS632-TPS632 (2023). 10.1200/JCO.2023.41.16_suppl.TPS632 Cite \| Source
A meta-analysis of cardiac toxicity of concurrent epirubicin and trastuzumab in early breast cancer. (journal article) Yang, Minghan \| Huang, Chiun-Sheng \| Chang, Dwan-Ying \| Chen, I-Chun \| Lin, Ching-Hung \| Lu, Yen-Shen Journal of Clinical Oncology, volume 41, issue 16_suppl, pages e12583-e12583 (2023). 10.1200/JCO.2023.41.16_suppl.e12583 Cite \| Source
Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58. (journal article) Pascual, Tomás \| Stover, Daniel G. \| Thuerigen, Astrid \| Sanchez-Bayona, Rodrigo \| Perou, Charles M. \| Ciruelos, Eva M \| Casas, Ana \| Spears, Patricia \| Roux, Estelle \| Su, Fei \| ... \| Prat, Aleix Journal of Clinical Oncology, volume 41, issue 16_suppl, pages TPS1125-TPS1125 (2023). 10.1200/JCO.2023.41.16_suppl.TPS1125 Cited by (1) \| Cite \| Source